Blue­bird hopes to raise up­wards of $100M by sell­ing shares

Blue­bird bio is look­ing for cash.

Wednes­day morn­ing, the gene ther­a­py biotech an­nounced that it was look­ing to sell 20 mil­lion shares of its stock $BLUE, which at Tues­day’s clos­ing price of $7.28, would trans­late to rough­ly $145 mil­lion. In ad­di­tion, as part of the of­fer­ing, un­der­writ­ers — in­clud­ing Gold­man Sachs and JP Mor­gan — can buy an ad­di­tion­al 3 mil­lion shares of stock, which would be around an­oth­er $20 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.